BEACON CRC: A randomized, 3-Arm, phase 3 study of Encorafenib (ENCO) and Cetuximab (CETUX) with or without Binimetinib (BINI) versus choice of either Irinotecan or FOLFIRI plus Cetuximab in BRAF V600E-mutant metastatic colorectal cancer

作者： Jayesh Desai , Scott Kopetz , Axel Grothey , Eric Van Cutsem , Rona Yaeger

DOI:

关键词: